Demonstration of an Aberrant Mast-cell Population with Clonal Markers in a Subset of Patients with "idiopathic" Anaphylaxis

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Jul 20

PMID 17638853

Citations 59

Authors

Cem Akin

Linda M Scott

Can N Kocabas

Nataliya Kushnir-Sukhov

Erica Brittain

Pierre Noel

Dean D Metcalfe

Affiliations

Soon will be listed here.

Abstract

Idiopathic anaphylaxis remains a perplexing disorder in which existing prophylactic therapy is inadequate. In this prospective study, we sought to determine whether patients with idiopathic anaphylaxis might have evidence for a clonal disorder of mast cells related to mastocytosis and for which novel targeted therapies might be considered. We report 12 patients with "idiopathic" anaphylaxis who did not exhibit either urticaria pigmentosa or the characteristic bone marrow biopsy finding of multifocal mast-cell aggregates observed in systemic mastocytosis. Of these 12 patients, 5 had evidence of 1 or more minor criteria for mastocytosis. C-KIT mutational analysis was positive for the 816D>V activating mutation in 3 of 3 patients in CD25(+) bone marrow cells where the analysis was performed. These results demonstrate the presence of an aberrant mast-cell population carrying clonal markers in a subset of patients diagnosed with "idiopathic" anaphylaxis, who may respond to inhibitors targeting mutated C-KIT. This intramural clinical trial was conducted in 2003 and 2004 and was registered at (http://clinicalcenter.nih.gov) with a study number 03-I-0010. Since the study is now closed, it is no longer available online.

Citing Articles

Cold-induced anaphylaxis: new insights into clinical and genetic characteristics.

Bizjak M, Korosec P, Kosnik M, Selb J, Bidovec-Stojkovic U, Svetina M Front Immunol. 2025; 16:1558284.

PMID: 40061949 PMC: 11885499. DOI: 10.3389/fimmu.2025.1558284.

Characterization of patients with clonal mast cells in the bone marrow with clinical significance not otherwise specified.

Ballul T, Sabato V, Valent P, Hermine O, Lortholary O, Rossignol J EClinicalMedicine. 2025; 80:103043.

PMID: 39877259 PMC: 11773267. DOI: 10.1016/j.eclinm.2024.103043.

When allergies have no name: is idiopathic anaphylaxis driven by co-factors?.

Elkhalifa S, Elbashir H, Abuzakouk M Front Allergy. 2024; 5:1468945.

PMID: 39493748 PMC: 11527779. DOI: 10.3389/falgy.2024.1468945.

Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria.

Solomon B, Khatri P J Allergy Clin Immunol. 2024; 155(1):213-218.e4.

PMID: 39278360 PMC: 11700772. DOI: 10.1016/j.jaci.2024.09.006.

Alpha-Tryptase as a Risk-Modifying Factor for Mast Cell-Mediated Reactions.

Shin H, Lyons J Curr Allergy Asthma Rep. 2024; 24(4):199-209.

PMID: 38460022 PMC: 11870015. DOI: 10.1007/s11882-024-01136-y.

References

Lam V, Kalesnikoff J, Lee C, Hernandez-Hansen V, Wilson B, Oliver J . IgE alone stimulates mast cell adhesion to fibronectin via pathways similar to those used by IgE + antigen but distinct from those used by Steel factor. Blood. 2003; 102(4):1405-13. DOI: 10.1182/blood-2002-10-3176. View

Escribano L, Orfao A, Villarrubia J, Cervero C, Lopez A, Marcos M . Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998; 91(8):2731-6. View

Escribano L, Akin C, Castells M, Orfao A, Metcalfe D . Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002; 81(12):677-90. DOI: 10.1007/s00277-002-0575-z. View

Hundley T, Gilfillan A, Tkaczyk C, Andrade M, Metcalfe D, Beaven M . Kit and FcepsilonRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells. Blood. 2004; 104(8):2410-7. DOI: 10.1182/blood-2004-02-0631. View

Garcia-Montero A, Jara-Acevedo M, Teodosio C, Sanchez M, Nunez R, Prados A . KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108(7):2366-72. DOI: 10.1182/blood-2006-04-015545. View

Florian S, Krauth M, Simonitsch-Klupp I, Sperr W, Fritsche-Polanz R, Sonneck K . Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes. Int Arch Allergy Immunol. 2005; 136(3):273-80. DOI: 10.1159/000083954. View

Akin C, Metcalfe D . Systemic mastocytosis. Annu Rev Med. 2004; 55:419-32. DOI: 10.1146/annurev.med.55.091902.103822. View

Akin C, Kirshenbaum A, Semere T, Worobec A, Scott L, Metcalfe D . Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol. 2000; 28(2):140-7. DOI: 10.1016/s0301-472x(99)00145-9. View

Akin C, Fumo G, Yavuz A, Lipsky P, Neckers L, Metcalfe D . A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004; 103(8):3222-5. DOI: 10.1182/blood-2003-11-3816. View

10.

Akin C . Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006; 8(4):412-9. PMC: 1867614. DOI: 10.2353/jmoldx.2006.060022. View

11.

Kalesnikoff J, Huber M, Lam V, Damen J, Zhang J, Siraganian R . Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival. Immunity. 2001; 14(6):801-11. DOI: 10.1016/s1074-7613(01)00159-5. View

12.

KRAFFT , Duncan , Bijwaard , Taubenberger , Lichy . Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review. Mol Diagn. 1999; 2(3):217-230. DOI: 10.1054/MODI00200217. View

13.

Koide T, Nakajima T, Makifuchi T, Fukuhara N . Systemic mastocytosis and recurrent anaphylactic shock. Lancet. 2002; 359(9323):2084. DOI: 10.1016/S0140-6736(02)08908-0. View

14.

Sonneck K, Florian S, Mullauer L, Wimazal F, Fodinger M, Sperr W . Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome. Int Arch Allergy Immunol. 2006; 142(2):158-64. DOI: 10.1159/000096442. View

15.

Valent P, Horny H, Escribano L, Longley B, Li C, Schwartz L . Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25(7):603-25. DOI: 10.1016/s0145-2126(01)00038-8. View

16.

Horny H, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B . Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol. 1998; 22(9):1132-40. DOI: 10.1097/00000478-199809000-00013. View

17.

Tkaczyk C, Horejsi V, Iwaki S, Draber P, Samelson L, Satterthwaite A . NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation. Blood. 2004; 104(1):207-14. DOI: 10.1182/blood-2003-08-2769. View

18.

Schwartz L . Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res. 2001; 25(7):553-62. DOI: 10.1016/s0145-2126(01)00020-0. View

19.

Pandey V, Mihara S, Fensome-Green A, Bolsover S, Cockcroft S . Monomeric IgE stimulates NFAT translocation into the nucleus, a rise in cytosol Ca2+, degranulation, and membrane ruffling in the cultured rat basophilic leukemia-2H3 mast cell line. J Immunol. 2004; 172(7):4048-58. DOI: 10.4049/jimmunol.172.7.4048. View

20.

Escribano L, Bellas C, Navalon R, Nunez R, Sperr W, Schernthaner G . Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001; 25(7):563-70. DOI: 10.1016/s0145-2126(01)00050-9. View